BioCentury
ARTICLE | Finance

Peanut Epicure

New money for DBV Tech to test Viaskin Peanut patch to treat peanut allergy

January 10, 2011 8:00 AM UTC

With €9.4 million ($25.5 million) in hand from a series C round, DBV Technologies believes it has enough cash to complete a pivotal study of allergy candidate Viaskin Peanut, a patch that delivers peanut proteins epicutaneously.

The round was led by new investors InnoBio Fund and Lundbeckfond Ventures. Other new investors Shire plc (LSE:SHP; NASDAQ:SHPGY) and Alto Invest joined existing investors Sofinnova Partners and allergy company ALK-Abello A/S (CSE:ALK-B)...